STOCKHOLM, SE / ACCESS Newswire / April 3, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN ...

After years of delays Pfizer and Eli Lilly’s tanezumab non-opioid pain drug is edging closer to approval, after it met targets in an osteoarthritis trial. Tanezumab is a nerve growth factor (NGF ...

we selected a candidate drug at the beginning of the year and presented preclinical data showing that ACD137 has at least as good analgesic effects as the antibody Tanezumab, and also potentially ...

After years in development, the FDA has started its review of Pfizer and Eli Lilly’s new painkiller tanezumab, one of two remaining drugs in the ill-fated nerve growth factor (NGF) inhibitor class.

Merck & Co., Inc. (NYSE:MRK) announced that a phase III study evaluating its blockbuster PD-L1 inhibitor, Keytruda in patients... Investors in Pfizer Inc. (NYSE:PFE) need to pay close attention to ...

Polydipsia and polyuria were not reported as statistically significant AEs in clinical trials of tanezumab, a similar medicine for humans (62), highlighting the species-specific nature of AEs. A ...